

Worldwide Healthcare Trust (WWH) ShareSoc Webinar 28/09/21
Responses to questions left unanswered at the end of the webinar

1. **How do Biotech / Healthcare investments respond to rising interest rates on borrowing? Or, do Biotechs typically not use corporate bonds for investments?**

Occasionally small cap biotech stocks will borrow money, usually through convertible bonds, but equity issuance is much more common. And that is our focus. Market timing is not in our playbook, typically, and innovation-driven valuation creation swamps any economic gyrations that may transiently impact share prices.

2. **Theranos has grabbed the headlines. Is this common amongst your screening of start-up companies?**

We do massive amounts of due diligence across the healthcare spectrum, including many IPO stocks. Whilst some boom, and some bust, very few are born out of fraud. Nevertheless, we are confident that our investment process would filter any such circumstances.

3. **What is your view on Clinical Research Organisations as an investment sector for the trust?**

CROs present an interesting investment opportunity for the Trust as there are several secular tailwinds that benefit the group. At this point however, we have limited exposure due to the significant rise in valuation as well as potentially difficult dynamics from COVID trial work falling off.